QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)

Prothena (PRTA) Stock Price, News & Analysis

$24.80
-0.36 (-1.43%)
(As of 12:47 PM ET)
Today's Range
$24.25
$25.34
50-Day Range
$24.75
$34.07
52-Week Range
$24.25
$79.65
Volume
306,392 shs
Average Volume
817,213 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.63

Prothena MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
186.3% Upside
$69.63 Price Target
Short Interest
Bearish
11.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Prothena in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$170,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.87) to ($4.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

297th out of 939 stocks

Pharmaceutical Preparations Industry

133rd out of 433 stocks

PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Prothena Corporation plc (PRTA)
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
PRTA Mar 2024 105.000 call
Prothena Full Year 2023 Earnings: Beats Expectations
RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)
Decoding 6 Analyst Evaluations For Prothena Corp
Earnings Outlook For Prothena Corp
Navigating 5 Analyst Ratings For Prothena Corp
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTA
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.63
High Stock Price Target
$90.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+186.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-147,030,000.00
Net Margins
-160.91%
Pretax Margin
-175.64%

Debt

Sales & Book Value

Annual Sales
$91.37 million
Book Value
$10.46 per share

Miscellaneous

Free Float
38,571,000
Market Cap
$1.31 billion
Optionable
Optionable
Beta
0.22
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

9 Wall Street analysts have issued 1-year target prices for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they anticipate the company's stock price to reach $69.63 in the next twelve months. This suggests a possible upside of 186.3% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2024?

Prothena's stock was trading at $36.34 at the start of the year. Since then, PRTA stock has decreased by 33.1% and is now trading at $24.32.
View the best growth stocks for 2024 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by $0.03. The biotechnology company had revenue of $0.32 million for the quarter, compared to analyst estimates of $2.15 million. Prothena had a negative trailing twelve-month return on equity of 24.84% and a negative net margin of 160.91%. The business's revenue for the quarter was down 99.4% on a year-over-year basis. During the same period last year, the firm posted $0.12 earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Prothena's major shareholders?

Prothena's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (7.90%), Price T Rowe Associates Inc. MD (7.90%), Wellington Management Group LLP (4.83%), Palo Alto Investors LP (3.09%), First Light Asset Management LLC (2.03%) and Vanguard Group Inc. (1.99%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners